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Background: Coronary heart disease is the leading cause of mortality in the world. One of the outcome indicators
recently used to measure hospital performance is 30-day mortality after acute myocardial infarction (AMI). This
indicator has proven to be a valid and reproducible indicator of the appropriateness and effectiveness of the
diagnostic and therapeutic process for AMI patients after hospital admission. The aim of this study was to examine
the determinants of inter-hospital variability on 30-day in-hospital mortality after AMI in Tuscany. This indicator is a
proxy of 30-day mortality that includes only deaths occurred during the index or subsequent hospitalizations.
Methods: The study population was identified from hospital discharge records (HDRs) and included all patients
with primary or secondary ICD-9-CM codes of AMI (ICD-9 codes 410.xx) that were discharged between January 1,
2009 and November 30, 2009 from any hospital in Tuscany. The outcome of interest was 30-day all-cause
in-hospital mortality, defined as a death occurring for any reason in the hospital within 30 days of the admission
date. Because of the hierarchical structure of the data, with patients clustered into hospitals, random-effects
(multilevel) logistic regression models were used. The models included patient risk factors and random intercepts
for each hospital.
Results: The study included 5,832 patients, 61.90% male, with a mean age of 72.38 years. During the study period,
7.99% of patients died within 30 days of admission. The 30-day in-hospital mortality rate was significantly higher
among patients with ST segment elevation myocardial infarction (STEMI) compared with those with non-ST
segment elevation myocardial infarction (NSTEMI). The multilevel analysis which included only the hospital variance
showed a significant inter-hospital variation in 30-day in-hospital mortality. When patient characteristics were added
to the model, the hospital variance decreased. The multilevel analysis was then carried out separately in the two
strata of patients with STEMI and NSTEMI. In the STEMI group, after adjusting for patient characteristics, some
residual inter-hospital variation was found, and was related to the presence of a cardiac catheterisation laboratory.
Conclusion: We have shown that it is possible to use routinely collected administrative data to predict mortality
risk and to highlight inter-hospital differences. The distinction between STEMI and NSTEMI proved to be useful to
detect organisational characteristics, which affected only the STEMI subgroup.
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Coronary heart disease, and in particular acute coronary
syndromes (ACS), is the leading cause of mortality in
the world [1]. Of the syndromes that comprise ACS,
ST-segment elevation acute myocardial infarction
(STEMI) and non-ST segment elevation acute myocar-
dial infarction (NSTEMI) have been reported to have
differing short-term prognosis and response to therapies
[2,3].
Although important steps have been taken in the
care of patients with these conditions, a substantial
proportion of patients do not receive effective treat-
ments, and population-based studies have been called
for to evaluate the successful translation of evidence-
based medicine into clinical practice [4]. As a result,
emphasis has increasingly been placed on the quality
of hospital services and on the equity of access to ef-
fective care for patients with acute myocardial infarc-
tion (AMI).
One of indicators that has proved to be a valid and re-
producible indicator of the appropriateness and effect-
iveness of the diagnostic and therapeutic process that
begins with the admission of patients with this condition
is 30-day mortality [5-10].
To assess the performance of health care services,
the Italian Tuscany region introduced in 2005 an
evaluation system based on the systematic collection
of indicators to examine the efficiency, effectiveness
and appropriateness of care for a number of clinical
conditions. Indicators were determined from adminis-
trative data sources, that are increasingly being used
to examine the quality of care and patient outcomes
and to compare hospital performance in Western
countries [11,12]. One of the outcome indicators re-
cently included in the Tuscan performance evaluation
system is 30-day in-hospital mortality after AMI,
that is a proxy of 30-day mortality including only
deaths occurred during the index or subsequent
hospitalizations.
The aim of this study was to examine the determi-
nants of inter-hospital variability in 30-day in-hospital
mortality after AMI in Tuscany, using an analytical strat-
egy to determine the influence of patient and organisa-
tional characteristics.
Specifically, because patients’ risk factors may vary
across hospitals, the inter-hospital comparison was car-
ried out using risk adjustment methods to control for
the patient case mix and by stratifying the patients
according to the presence or absence of ST-segment ele-
vation. Multilevel models were used, as has been
strongly recommended [6], to take into account the
effects of clustering of patients into hospitals and of hos-
pital characteristics, including organisational variables,
that may affect short-term mortality.Methods
The study population was identified from hospital dis-
charge records (HDRs), and included all patients with pri-
mary or secondary ICD-9-CM codes of AMI (ICD-9 codes
410.xx) that were discharged between January 1, 2009 and
November 30, 2009 from any hospital in Tuscany.
Data on hospital discharges in Tuscany region are rou-
tinely entered at hospital level into the HDR database.
The hospital information system collects demographic
information and ICD-9-CM diagnoses and procedures.
These data are sent every 3 months for quality check to
the Regional Health Information System Office that
gives feedback to the hospitals on logical inconsistencies
and missing data. Data are then corrected, completed
and sent back the Regional Health Information System
Office. As a results of this process, only a limited per-
centage of records are discarded, given that hospital re-
imbursement is based on these routine data.
The study was carried out in compliance with the
Italian law on privacy (Art. 20–21, DL 196/2003) and
the regulations of the Health Authorities of Tuscany Re-
gion on data management. Data were anonymized at the
Regional Health Information System Office where each
patient was assigned a unique identifier that is the same
for all administrative databases. This identifier does not
allow to trace the patient’s identity and other sensitive
data. When anonymized administrative data are used to
inform health care planning activities, the study is
exempt from notification to the Ethics Committee pro-
vided written consent is obtained to use patient’s infor-
mation stored in the hospital databases.
Records were excluded from the analysis on the basis
of the following criteria:
1. Admissions preceded by a diagnosis of AMI in the
preceding 8 weeks. This was done to exclude
sequelae of a previous episode, according to the ICD-
9-CM classification which defines "8 weeks" as the
limit for a single "episode of care";
2. Admission lasting less than 2 days with discharge
home;
3. Transfers from other hospitals;
4. Patients not resident in Tuscany;
5. Patients aged under 18 years or more than 100 years;
6. A diagnostic code 410.9 (myocardial infarction of
unspecified site).
If patients were transferred, mortality was attributed
to the hospital to which the patient was initially admit-
ted [12].
Data
The outcome of interest was 30-day all-cause in-hospital
mortality, defined as a death occurring for any reason
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hospitalization or in any subsequent hospitalization. The
follow-up was performed through a deterministic record
linkage procedure of hospital discharge records from all
Tuscan hospitals, using the unique patient identifier.
The period of follow-up was determined as 30 days from
the index admission. Our outcome differs from 30-day
mortality used by other authors that also include deaths
occurring out of the hospital, within 30 days of the index
admission [13,14]. We could not analyse out-of-hospital
deaths because they can be obtained from the mortality
registry database available to researchers only after a
time lag of several years.
Hospitals were categorised according to a presence or
absence of the cardiac catheterisation laboratory, defined
as “a laboratory operating in a hospital with in-house
cardiovascular surgical support, in which both diagnostic
and therapeutic procedures are performed on the heart
and great vessels for a wide variety of cardiovascular dis-
eases” [15].
Information on the following variables, that might in-
fluence the outcome of interest and whose distribution
may differ across hospitals, was retrieved from the
HDRs: patient age, sex and comorbidities. The ICD-9-
CM codes were used to define the presence or absence
of specific comorbidities (hematologic diseases, previous
AMI episodes, cerebrovascular diseases, vascular dis-
eases, chronic nephropathies, tumours, diabetes, hyper-
tensive disease, other forms of ischemic heart disease,
conduction disorders and cardiac dysrhythmias, and
chronic obstructive pulmonary disease) at the index ad-
mission and in the previous 2 years.
According to the ICD-9-CM classification that was
adopted in Italy in 2007, the type of ST-segment eleva-
tion was determined as follows: patients with 410.1x–
410.6x or 410.8x were defined as STEMI; patients with
410.7x were defined as NSTEMI. Codes 410.9 were
excluded from the analyses [16].
The validity of the ICD-9-CM coding in the Tuscany
region compared with clinical data was examined in sep-
arate samples collected in the framework of AMI-
Florence registry data [17] and in the IN-ACS study [18].
Sensitivity, specificity and PPV were 90.4%, 71.9%, 69.5%
in AMI-Florence (2009 data) and 98%, 90.4% and 96% in
IN-ACS study, supporting the validity of the codes.
Statistical analysis
We determined the differences in patient characteristics
according to the two hospital types (presence/absence of
a cardiac catheterisation laboratory) using Pearson’s χ2
test or the Student’s t-test as appropriate. Comparison of
30-day in-hospital mortality rates between patients with
STEMI and NSTEMI was performed using Pearson’s χ2
test.Because of the hierarchical structure of our data, with
patients clustered into hospitals, we fitted random-
effects (also known as multilevel or hierarchical) logistic
regression models. The models included patient risk fac-
tors and random intercepts for each hospital, and
allowed analysis of hospitals with a low case load
[10,11,19,20]. We built several two-level models. The
first model included only the random intercept to esti-
mate inter-hospital variability in overall mortality rate.
The second model contained relevant patient comorbid-
ities (identified in a preliminary stepwise logistic regres-
sion model), age, gender and STEMI/NSTEMI
categorisation. The significance level of entry and re-
moval was set at 0.05. Age and gender were forced into
the model. In the final model, we added the presence of
a cardiac catheterisation laboratory in the hospital. In
addition, we tested the interactions between outcome,
AMI phenotype and gender, and then carried out a
multilevel analysis on patients with STEMI and
NSTEMI separately.
We estimated the odds ratios (ORs) with 95% confi-
dence intervals (CIs) for patient and hospital-related
characteristics and the random variance (σ2), which is a
measure of inter-hospital variation. We used the area
under the ROC curve to assess the discriminative ability
of the model in predicting 30-day in-hospital mortality.
This area (alternatively named c-index) varies from 0.5
to 1, with larger values denoting better model perform-
ance. We also reported other goodness of fit indexes, in-
cluding pseudo R2, the Wald χ2 test, Akaike information
criterion (AIC) and Bayesian information criterion
(BIC). Then, we calculated the adjusted hospital-specific
mortality rates with 95% CIs to identify hospitals with
mortality rates significantly different from the adjusted
overall mortality rate. Hospital-specific adjusted mortal-
ity rates were calculated as the antilogit function of the
random intercepts derived from the multilevel logistic
regression model which included patient characteristics.
The adjusted overall mortality rate was obtained by tak-
ing the antilogit function of the intercept estimated from
the same model. We expressed these results in terms of
RSMRs (risk-standardised mortality rates) [12]. RSMRs
with 95% CIs were calculated as hospital-specific
adjusted mortality rates over the adjusted overall mortal-
ity rate, multiplied by the unadjusted overall mortality
rate.
Finally, we used funnel plots as an alternative method
for inter-hospital comparison. Funnel plots are scatter
plots of unadjusted 30-day in-hospital mortality rates
against the number of patients discharged from each
hospital [21]. We superimposed on the plot 95%
(≈2 standard deviations) and 99.8% (≈3 standard devia-
tions) control limits around the crude overall 30-day
in-hospital mortality rate. We chose to use the crude
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results from funnel plots comparable to the RSMRs
from multilevel analyses.
Statistical analyses were performed using Stata soft-
ware, version 12 (StataCorp LP, College Station, TX,
USA).
Results
We extracted a total of 6,267 HDRs of patients with
AMI from 37 hospitals, 11 of which (29.73%) had a car-
diac catheterisation laboratory. Ten of these operated
24-h 7 days a week, one was a 12-h laboratory operating
12 h for 7 days a week, and had an associated 24-h la-
boratory about 26 km away; 316 HDRs (5.03%) were
excluded because their diagnostic code was 410.9.
The study population included 5,832 patients (61.90%
male, mean age 72.38 years) admitted to 37 hospitals
(Table 1); 114 patients had multiple AMI. The overall
proportion of patients with STEMI was 47.15%.Table 1 Patient characteristics according to the presence of a
Characteristics All
(n=5,832
Age in years, mean [SD] 72.38 [13
Gender (%)
Male 3,610 (61
Female 2,222 (38
Hospital stay in days, mean [SD] 6.79 [5.62
Comorbidities (%)
No 3,918 (67
Yes 1,914 (32
Specific comorbidities (%)
Hematologic diseases 181 (3.10
History of heart failure 352 (6.04
Cerebrovascular diseases 273 (4.68
History of cerebrovascular diseases 261 (4.48
Vascular diseases 259 (4.44
History of vascular diseases 177 (3.03
Chronic nephropathies 470 (8.06
History of chronic nephropathies 237 (4.06
History of tumours 167 (2.86
History of diabetes 373 (6.40
History of hypertensive disease 582 (9.98
History of other forms of ischemic heart disease 597 (10.2
History of conduction disorders and cardiac dysrhythmias 288 (4.94
History of COPD 182 (3.10
ST-segment elevation (%)
NSTEMI 3,082 (52
STEMI 2,750 (47
COPD Chronic obstructive pulmonary disease, SD standard deviation, STEMI ST elevPatients admitted to hospitals with a cardiac catheter-
isation laboratory were significantly younger, less comor-
bid, more frequently male, had STEMI, and had a longer
hospital stay (Table 1).
During the study period, 7.99% of patients (interquar-
tile range, 6.45–11.59%) died within 30 days of admis-
sion. The 30-day in-hospital mortality rate was
significantly higher among patients with STEMI com-
pared with those with NSTEMI (STEMI: 9.89%, inter-
quartile range 5.85–18.18%; NSTEMI: 6.29%,
interquartile range 3.73–7.92%; Pearson’s χ2 (d.f.) =
27.46 (1), p < 0.001).
Multilevel logistic regression analysis
In the overall sample, the multilevel model that included
only the hospital-specific random effect showed a signifi-
cant inter-hospital variation in 30-day in-hospital mor-
tality (σ2 = 0.12, p < 0.001) (Table 2). When patient
characteristics, including age, gender, comorbidities andcardiac catheterisation laboratory
)
Presence of cardiac catheterisation lab.
No (n=2,315) Yes (n=3,517) p-value
.05] 74.62 [12.39] 70.90 [13.26] <0.001
<0.001
.90) 1,335 (57.67) 2,275 (64.69)
.10) 980 (42.33) 1,242 (35.31)
] 6.43 [5.54] 7.03 [5.67] <0.001
<0.001
.18) 1,412 (60.99) 2,506 (71.25)
.82) 903 (39.01) 1,011 (28.75)
) 81 (3.50) 100 (2.84) 0.158
) 184 (7.95) 168 (4.78) <0.001
) 139 (6.00) 134 (3.81) <0.001
) 123 (5.31) 138 (3.92) 0.012
) 107 (4.62) 152 (4.32) 0.588
) 77 (3.33) 100 (2.84) 0.293
) 234 (10.11) 236 (6.71) <0.001
) 128 (5.53) 109 (3.10) <0.001
) 81 (3.50) 86 (2.45) 0.018
) 185 (7.99) 188 (5.35) <0.001
) 278 (12.01) 304 (8.64) <0.001
4) 294 (12.70) 303 (8.62) <0.001
) 152 (6.57) 136 (3.87) <0.001
) 105 (4.54) 77 (2.19) <0.001
<0.001
.85) 1,509 (65.18) 1,573 (44.73)
.15) 806 (34.82) 1,944 (55.27)
ation myocardial infarction, NSTEMI Non-ST elevation myocardial infarction.
Table 2 Odds ratios and 95% CIs for multilevel logistic models estimating 30-day in-hospital mortality in the overall
sample
Hierarchical null model Hierarchical model without
presence of a cardiac
catheterisation lab.
Hierarchical model with
presence of a cardiac
catheterisation lab.
Patients Characteristics
Gender (male vs. female) – 1.10 (0.90–1.36) 1.09 (0.89–1.35)
Age (years) – 1.09 (1.08–1.10) 1.09 (1.08–1.10)
History of COPD – 1.99 (1.31–3.01) 1.91 (1.26–2.88)
History of heart failure – 1.47 (1.07–2.02) 1.46 (1.06–2.00)
History of cerebrovascular diseases – 1.49 (1.04–2.14) 1.49 (1.04–2.14)
Cerebrovascular diseases – 1.45 (1.01–2.09) 1.42 (0.99–2.04)
History of tumours – 2.65 (1.73–4.05) 2.55 (1.67–3.90)
ST-segment elevation (STEMI vs. NSTEMI) – 2.26 (1.83–2.78) 2.31 (1.88–2.84)
Hospital Characteristic
Presence of cardiac catheterisation lab. – – 0.71 (0.58–0.87)
Hospital Variance
σ2 (p-value)* 0.12 (<0.001) 0.05 (0.084) <0.01 (1.000)
Goodness of fit
Pseudo R2 – 0.31 0.32
Wald χ2 (p-value) – 335.25 (<0.001) 350.58 (<0.001)
AIC 3,261.08 2,843.00 2,836.27
BIC 3,264.30 2,859.11 2,853.99
* p-value from LR (likelihood ratio) test vs. logistic regression of σ2 = 1.
CI confidence interval, AIC Akaike Information Criterion, BIC Bayesian Information Criterion.
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model, the hospital variance decreased (σ2 = 0.05, p =
0.084). To account for residual hospital variability, we
included in the model the presence of a cardiac catheter-
isation laboratory. This variable was significantly asso-
ciated with 30-day in-hospital mortality: specifically,
patients from hospitals with a cardiac catheterisation la-
boratory were 29% less likely to die. This final model
had a c-index of 0.78, denoting a satisfactory perform-
ance in predicting the outcome.
We found a significant interaction between outcome
and AMI phenotype, and a non-significant interaction
between outcome and gender. The multilevel analysis
was hence carried out separately in the two strata of
patients with STEMI and NSTEMI. In patients with
STEMI, some residual inter-hospital variation was
found, even after adjusting for patient characteristics
(Table 3). Incorporating the presence of a cardiac cath-
eterisation laboratory to the model accounted for a sig-
nificant proportion of hospital variability (the hospital
variance decreased to 0.08, p = 0.046). Patients with
STEMI from hospitals with a cardiac catheterisation la-
boratory were 41% less likely to die within 30 days. In
contrast, 30-day in-hospital mortality rates of patients
with NSTEMI showed no variation among hospitals and
the presence of a cardiac catheterisation laboratory didnot influence the outcome. The c-index for the STEMI
and NSTEMI models was 0.76 and 0.79, respectively.
According to AIC and BIC, among patients with STEMI
the model with patient and hospital characteristics gave
the best fit, while among patients with NSTEMI the best
model was the one which included only patient charac-
teristics. The analyses of residuals did not reveal the
presence of influential observations.
Comparison of hospital-specific 30-day in-hospital
mortality rates with the overall rate
Figure 1 shows the RSMRs for the overall sample com-
pared with the overall 30-day in-hospital mortality rate.
One hospital (#23) displayed a significantly higher mor-
tality rate compared with the overall rate, with a wide
confidence interval related to its small number of AMI
patients.
Stratification by ST-segment elevation revealed two
hospitals (#16 and 23) which had mortality rates differ-
ing significantly from the overall rate in patients with
STEMI (Figure 2), and none in patients with NSTEMI.
Figures 3 and 4 show the funnel plots for STEMI and
NSTEMI that depict the relationship between un-
adjusted mortality rates and the number of discharges.
Regarding STEMI, nine hospitals exceeded the upper
boundary of the 95% control limit for the crude 30-day
Table 3 Odds ratios and 95% CIs for multilevel logistic models estimating 30-day in-hospital mortality by ST-segment
elevation
STEMI NSTEMI
Hierarchical
null model
Hierarchical
model without
presence of a
cardiac
catheterisation
lab.
Hierarchical
model with
presence of a
cardiac
catheterisation
lab.
Hierarchical
null model
Hierarchical
model without
presence of a
cardiac
catheterisation
lab.
Hierarchical
model with
presence of a
cardiac
catheterisation
lab.
Patients Characteristics
Gender (male vs. female) – 1.15 (0.86–1.52) 1.14 (0.86–1.51) – 1.02 (0.74–1.40) 1.01 (0.74–1.39)
Age (years) – 1.08 (1.06–1.09) 1.08 (1.06–1.09) – 1.11 (1.09–1.13) 1.11 (1.09–1.14)
History of COPD – 2.89 (1.51–5.53) 2.67 (1.40–5.11) – 1.75 (1.02–3.03) 1.73 (1.00–2.99)
History of diabetes – – – – 1.65 (1.02–2.67) 1.64 (1.01–2.65)
History of cerebrovascular diseases – – – – 1.79 (1.08–2.97) 1.80 (1.09–2.98)
Cerebrovascular diseases – 1.86 (1.13–3.07) 1.81 (1.10–2.98) – – –
History of tumours – 3.08 (1.70–5.58) 2.93 (1.62–5.32) – 2.49 (1.34–4.65) 2.50 (1.34–4.67)
Vascular diseases – 2.05 (1.17–3.59) 2.05 (1.17–3.58) – – –
History of other forms of ischemic heart diseases – – – – 0.54 (0.33–0.86) 0.54 (0.34–0.86)
History of heart failure – – – – 1.87 (1.21–2.89) 1.87 (1.21–2.88)
Hospital Characteristic
Presence of cardiac catheterisation lab. – – 0.59 (0.42–0.85) – – 0.89 (0.65–1.20)
Hospital Variance
σ2 (p-value)* 0.42 (<0.001) 0.17 (0.002) 0.08 (0.046) <0.01 (1.000) <0.01 (1.000) <0.01 (1.000)
Goodness of fit
Pseudo R2 – 0.27 0.29 – 0.37 0.37
Wald χ2 (p-value) – 162.44 (<0.001) 174.44 (<0.001) – 151.59 (<0.001) 152.17 (<0.001)
AIC 1,749.24 1,554.80 1,549.84 1,464.31 1,273.26 1,274.64
BIC 1,753.46 1,567.69 1,564.34 1,467.36 1,288.52 1,291.43
* p-value from LR (likelihood ratio) test vs. logistic regression of σ2 = 1.
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the boundaries for both STEMI and NSTEMI.
Discussion
We compared 30-day in-hospital mortality rates after
AMI among 37 hospitals in Tuscany region using ad-
ministrative data sources. The standardised period of 30
days was chosen to ensure a fair inter-hospital compari-
son and to prevent differences in length of stay from
affecting the measurement. Our results indicate an over-
all mortality rate of 7.99%, with a significant inter-
hospital variability. This variability was largely accounted
for by patient characteristics, including the presence or
absence of ST-segment elevation, and partly by the pres-
ence of a cardiac catheterisation laboratory in the hos-
pital. Stratified analyses on patients with STEMI and
NSTEMI revealed that the presence of a cardiac cath-
eterisation laboratory influenced 30-day in-hospital mor-
tality only among patients with STEMI. The power of
the predictive models for STEMI and NSTEMI was sat-
isfactory (c-index 0.76 and 0.79).Our 30-day in-hospital mortality rates were within the
range of those reported for the US and European popu-
lation (overall 7.8–16.1, STEMI 5.9–15.0, NSTEMI 3.0–
14.0) [2,18,22-26].
The overall proportion of patients with STEMI was
47.15%, which is consistent with the rates reported by
Yeh et al. [22], Rogers et al. [27], Ruff et al. [4], and
with the recent trend of a decrease in STEMI com-
pared with NSTEMI in Western countries. The large
variability among hospitals in the proportion of
STEMI and the differential risk related to this condi-
tion supports the inclusion of this variable, in addition
to comorbidities, in risk adjustment models, to dimin-
ish the effect of case mix, in line with the literature
[2,28-32]. The classification STEMI/NSTEMI rests
upon the validity of coding for these diagnoses. In
Tuscany region, the sensitivity and specificity of the
STEMI/NSTEMI diagnosis based on the fourth digit
of ICD-9-CM AMI codes is in line with US studies
based on the National Registry of Myocardial Infarc-
tion [33,34].
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hospital with the regional benchmark, in the multilevel
analyses we identified one hospital with mortality signifi-
cantly higher than the regional rate. Restricting the ana-
lyses to patients with STEMI revealed two hospitals with
an increased mortality compared with the overall Tus-
cany rate. Using funnel plots, we identified ten hospitals
with a performance significantly poorer than the re-
gional benchmark for STEMI patients. This suggests
that funnel plots overemphasise regional discrepancies
in the performance of small-volume hospitals. We argue
that inter-hospital comparisons should preferably be
performed using multilevel analyses, because they
“minimize the impact of small sample sizes by borrowing
power across the entire sample and ensuring that hospi-
tals with small numbers are not identified as outliers be-
cause of adverse events in just a few patients” [10].
Moreover, our data show the importance of adjusting for
patient characteristics.
Regarding the impact of organisational characteristics
on outcome, we found that the presence of a cardiac
catheterisation laboratory in the hospital accounted for
a lower 30-day in-hospital mortality only in patients
with STEMI. Our results are consistent with two
New Zealand studies, showing that patients hospitalised
for ACS, if admitted to a hospital without a cardiac cath-
eterisation laboratory, suffered delays in diagnosis and
subsequent revascularisation [35,36]. In contrast, evi-
dence from other studies suggests that the risk of death
in patients with STEMI, admitted to a hospital equipped
with a cardiac catheterisation laboratory, does not differ
significantly from that of patients admitted to a hospital
without the laboratory [37,38]. A possible explanation of
this lack of difference is that a reduction in the risk of
death is achieved when reperfusion is performed within
a short time, either in the same hospital or by transfer-
ring the patient to another facility. This is corroborated
by a meta-analysis carried out on patients with STEMI
[39]. In addition, an Italian study found that implement-
ing a "reperfusion network" at the regional level effect-
ively reduced the rates of hospital mortality and major
cardiovascular and cerebrovascular events in the year
following the index admission [40]. A recent study
showed that hospitals with high-quality medical and
interventional management had better outcomes [41],
and another report differentiated high-performing hospi-
tals by an organisational culture that supported efforts
to improve AMI care [42]. Unfortunately, information
on medical treatments and door-to-balloon time is not
available in the hospital discharge database and we can-
not provide data to support or disprove these findings.
In our study, although some of the hospitals without a
cardiac catheterisation laboratory had good outcomes,
the hospitals that showed the best outcomes provedto be those equipped with a cardiac catheterisation
laboratory.Limitations
Our results should be interpreted bearing in mind the
strengths and weaknesses of the use of routine adminis-
trative databases for inter-hospital comparison of 30-day
in-hospital mortality after AMI. While hospital discharge
records are widely available at reasonable cost, they do
not provide clinical data and information on medical
treatments that can influence inter-hospital differences
[43]. It is therefore possible that differences in the sever-
ity of cases in this study are not accounted for. However,
evidence from a large Canadian study [8] suggested that
the use of detailed clinical data for inter-hospital com-
parison of AMI mortality rates does not result in a re-
duction in the number of hospitals with adjusted AMI
mortality rates higher than expected.
It is also possible that comorbidity is underreported in
some hospitals, which may lead to an overestimation of
adjusted death rates for those hospitals. Another poten-
tial source of bias may be that some hospital recorded
secondary diagnoses more accurately than others, which
may have an impact if hospitals that code comorbidities
poorly also provide better or worse care than other hos-
pitals. Last, we chose to use multilevel logistic regression
analyses with a dichotomous outcome. Other models in-
cluding time to death, such as frailty survival models,
would have been possible. However, given the lack of in-
formation on deaths occurring at home, we preferred to
use a simpler model.Conclusions
We have shown that it is possible to use routinely col-
lected administrative data to predict, with satisfactory
power, the short-term risk of death in AMI patients, and
to highlight inter-hospital differences. The distinction
between STEMI and NSTEMI proved to be useful to
identify inter-hospital variations, which affected only the
STEMI subgroup.
Our results have important implications in terms of
health care policy. We confirm that the use of adminis-
trative data sources for monitoring mortality routinely is
potentially useful in quality assessment and improve-
ment efforts. In particular, the variability in adjusted
mortality rates among hospitals suggests the need to de-
velop efficient auditing activities to detect critical aspects
of the organisation. Our data showed the beneficial ef-
fect of the presence of a cardiac catheterisation labora-
tory in the hospital, and support the view that timely
reperfusion may significantly decrease short-term mor-
tality in patients with AMI. We suggest that an efficient
reperfusion network can achieve this goal.
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